These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Cumberbatch MJ, Hill RG, Hargreaves RJ. Eur J Pharmacol; 1998 Nov 27; 362(1):43-6. PubMed ID: 9865528 [Abstract] [Full Text] [Related]
9. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Martin GR, Robertson AD, MacLennan SJ, Prentice DJ, Barrett VJ, Buckingham J, Honey AC, Giles H, Moncada S. Br J Pharmacol; 1997 May 27; 121(2):157-64. PubMed ID: 9154322 [Abstract] [Full Text] [Related]
10. Zolmitriptan for migraine. Med Lett Drugs Ther; 1998 Feb 27; 40(1021):27-8. PubMed ID: 9505961 [No Abstract] [Full Text] [Related]
11. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Villalón CM, Centurión D, Valdivia LF, De Vries P, Saxena PR. Proc West Pharmacol Soc; 2002 Feb 27; 45():199-210. PubMed ID: 12434581 [Abstract] [Full Text] [Related]
17. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Goadsby PJ, Yates R. Headache; 2006 Jan 27; 46(1):138-49. PubMed ID: 16412161 [Abstract] [Full Text] [Related]